| Customization: | Available |
|---|---|
| Powder: | Yes |
| Customized: | Customized |
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
Baricitinib, sold under the brand name Olumiant among others, is a drug for the treatment of rheumatoid arthritis (RA) in adults whose disease was not well controlled using RA medications called tumor necrosis factor (TNF) antagonists. It acts as an inhibitor of janus kinase (JAK), blocking the subtypes JAK1 and JAK2. The drug is approved for use in the European Union and the United States
1. It is used for the treatment of moderate to severe active rheumatoid arthritis (RA) in adults. Patients with intolerance to one or more anti-rheumatic drugs can be treated with this product. This product can be treated as a single agent or combined with a Combined treatment of methotrexate in Chemicalbook therapy. The efficacy of baricitinib in the treatment of psoriasis, diabetic nephropathy, atopic dermatitis, systemic lupus erythematosus and other diseases is currently in phase II clinical stage.
2. Used in the field of scientific research and chemical reagent.
Baricitinib (baricitinib) obtained FDA emergency authorization (EUA) to be used in combination with Redecivir to treat patients who require supplemental oxygen, intubation ventilation or extracorporeal membrane oxygenation, children over 2 years of age, or adult hospitalized patients with new coronary pneumonia or Suspected patient. The FDA emergency authorization is based on a clinical trial (ACTT-2) conducted by the National Institute of Allergy and Infectious Diseases (ACTT-2). Compared with radcivir monotherapy, baritinib is combined with radcivir. It can reduce the patient's recovery time during the 29-day treatment period.
){kind=link}